Clinical success of CD19-directed chimeric antigen receptor T-cell therapy in leukemia has led to increased interest in applying this to other hematological malignancies – the authors thus summarize clinical trial results using this therapy in multiple myeloma.
Ormhøj M et al. Curr Hematol Malig Rep 2017; 12: 119–125. doi:10.1007/s11899-017-0373-2
Results from this preclinical study indicate that blocking programmed death-1 (PD-1)/PD-1 ligand interactions in conjunction with other immune checkpoint proteins provides synergistic anti-tumor efficacy following lymphodepletive doses of whole body irradiation.
Jing W et al. J Immunotherapy Cancer 2015; 3: 2. doi:10.1186/s40425-014-0043-z
An evaluation of the development of three distinct immunotherapy platforms for lymphoma treatment: chimeric antigen receptor T-cell therapy, bispecific T-cell engagers, and immune checkpoint inhibitors.
Mackall et al. review immunotherapies with established efficacy in pediatric cancers as well as immunotherapies under study. The authors also highlight the emerging science driving this rapidly moving field.